Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis

Redox Biology

Volumn 6, Issue , 2015, Pages 565-577

  Liu, Rui Ming ^a   Desai, Leena P ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Fibrosis; NADPH oxidases; Oxidative stress; PAI 1; TGF

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CELL ACTIVATION; CELL DIFFERENTIATION; ENZYME INDUCTION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; FIBROSIS; GENE EXPRESSION; HUMAN; MOLECULAR PATHOLOGY; MYOFIBROBLAST; NONHUMAN; OXIDATION REDUCTION STATE; PLASMINOGEN ACTIVATOR INHIBITOR 1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHYSIOLOGY;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; HUMANS; MITOCHONDRIA; NADPH OXIDASE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN SPECIES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84944906108     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.09.009     Document Type: Review

References (264)

1. Manoury B., Nenan S., Leclerc O., Guenon I., Boichot E., Planquois J.M., Bertrand C.P., Lagente V. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir. Res. 2005, 6:11.
2. Lenz A.G., Costabel U., Maier K.L. Oxidized BAL fluid proteins in patients with interstitial lung diseases. Eur. Respir. J. 1996, 9:307-312.
3. Rottoli P., Magi B., Cianti R., Bargagli E., Vagaggini C., Nikiforakis N., Pallini V., Bini L. Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005, 5:2612-2618.
4. Psathakis K., Mermigkis D., Papatheodorou G., Loukides S., Panagou P., Polychronopoulos V., Siafakas N.M., Bouros D. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. Eur. J. Clin. Investig. 2006, 36:362-367.
5. Liu R.M., Gaston Pravia K.A. Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. Free. Radic. Biol. Med. 2010, 48:1-15.
6. Broekelmann T.J., Limper A.H., Colby T.V., McDonald J.A. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 1991, 88:6642-6646.
7. Bergeron A., Soler P., Kambouchner M., Loiseau P., Milleron B., Valeyre D., Hance A.J., Tazi A. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur. Respir. J. 2003, 22:69-76.
8. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Investig. 2005, 115:209-218.
9. Tzortzaki E.G., Antoniou K.M., Zervou M.I., Lambiri I., Koutsopoulos A., Tzanakis N., Plataki M., Maltezakis G., Bouros D., Siafakas N.M. Effects of antifibrotic agents on TGF-[beta]1, CTGF and IFN-[gamma] expression in patients with idiopathic pulmonary fibrosis. Respir. Med. 2007, 101:1821-1829.
10. Brosius F. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev. Endocr. Metab. Disord. 2008, 9:245-254.
11. Fahy R.J., Lichtenberger F., McKeegan C.B., Nuovo G.J., Marsh C.B., Wewers M.D. The acute respiratory distress syndrome: a role for transforming growth factor-beta 1. Am. J. Respir. Cell. Mol. Biol. 2003, 28:499-503.
12. Williams A.O., Flanders K.C., Saffiotti U. Immunohistochemical localization of transforming growth factor-beta 1 in rats with experimental silicosis, alveolar type II hyperplasia, and lung cancer. Am. J. Pathol. 1993, 142:1831-1840.
13. Coker R.K., Laurent G.J., Shahzeidi S., Lympany P.A., du Bois R.M., Jeffery P.K., McAnulty R.J. Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am. J. Pathol. 1997, 150:981-991.
14. Rube C.E., Uthe D., Schmid K.W., Richter K.D., Wessel J., Schuck A., Willich N., Rube C. Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2000, 47:1033-1042.
15. Kumar R.K., Herbert C., Foster P.S. Expression of growth factors by airway epithelial cells in a model of chronic asthma: regulation and relationship to subepithelial fibrosis. Clin. Exp. Allergy 2004, 34:567-575.
16. Ellmers L.J., Scott N.J.A., Medicherla S., Pilbrow A.P., Bridgman P.G., Yandle T.G., Richards A.M., Protter A.A., Cameron V.A. Transforming growth factor-{beta} blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction. Endocrinology 2008, 149:5828-5834.
17. Churg A., Zhou S., Preobrazhenska O., Tai H., Wang R., Wright J.L. Expression of profibrotic mediators in small airways versus parenchyma after cigarette smoke exposure. Am. J. Respir. Cell. Mol. Biol. 2009, 40:268-276.
18. Ng Y.Y., Chen Y.M., Tsai T.J., Lan X.R., Yang W.C., Lan H.Y. Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. Am. J. Nephrol. 2009, 29:43-53.
19. Hardie W.D., Le Cras T.D., Jiang K., Tichelaar J.W., Azhar M., Korfhagen T.R. Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L741-L749.
20. Lee C.G., Cho S.J., Kang M.J., Chapoval S.P., Lee P.J., Noble P.W., Yehualaeshet T., Lu B., Flavell R.A., Milbrandt J., Homer R.J., Elias J.A. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J. Exp. Med. 2004, 200:377-389.
21. Vicencio A.G., Lee C.G., Cho S.J., Eickelberg O., Chuu Y., Haddad G.G., Elias J.A. Conditional overexpression of bioactive transforming growth factor-beta1 in neonatal mouse lung: a new model for bronchopulmonary dysplasia?. Am. J. Respir. Cell Mol. Biol. 2004, 31:650-656.
22. Sime P.J., Xing Z., Graham F.L., Csaky K.G., Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin. Investig. 1997, 100:768-776.
23. Kolb M., Bonniaud P., Galt T., Sime P.J., Kelly M.M., Margetts P.J., Gauldie J. Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. Am. J. Respir. Cell Mol. Biol. 2002, 27:141-150.
24. Bonniaud P., Margetts P.J., Kolb M., Schroeder J.A., Kapoun A.M., Damm D., Murphy A., Chakravarty S., Dugar S., Higgins L., Protter A.A., Gauldie J. Progressive transforming growth factor {beta}1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am. J. Respir. Crit. Care Med. 2005, 171:889-898.
25. Liu R.M., Vayalil P.K., Ballinger C., Dickinson D.A., Huang W.T., Wang S., Kavanagh T.J., Matthews Q.L., Postlethwait E.M. Transforming growth factor beta suppresses glutamate-cysteine ligase gene expression and induces oxidative stress in a lung fibrosis model. Free. Radic. Biol. Med. 2012, 53:554-563.
26. Huang W.T., Vayalil P.K., Miyata T., Hagood J., Liu R.M. Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am. J. Respir. Cell Mol. Biol. 2012, 46:87-95.
27. Horowitz J.C., Rogers D.S., Simon R.H., Sisson T.H., Thannickal V.J. Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am. J. Respir. Cell Mol. Biol. 2008, 38:78-87.
28. Mackinnon A.C., Gibbons M.A., Farnworth S.L., Leffler H., Nilsson U.J., Delaine T., Simpson A.J., Forbes S.J., Hirani N., Gauldie J., Sethi T. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am. J. Respir. Crit. Care Med. 2012, 185:537-546.
29. Reilkoff R.A., Peng H., Murray L.A., Peng X., Russell T., Montgomery R., Feghali-Bostwick C., Shaw A., Homer R.J., Gulati M., Mathur A., Elias J.A., Herzog E.L. Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-beta1-induced pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2013, 187:180-188.
30. Giri S.N., Hyde D.M., Hollinger M.A. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993, 48:959-966.
31. Higashiyama H., Yoshimoto D., Kaise T., Matsubara S., Fujiwara M., Kikkawa H., Asano S., Kinoshita M. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp. Mol. Pathol. 2007, 83:39-46.
32. Wang Q., Wang Y., Hyde D.M., Gotwals P.J., Koteliansky V.E., Ryan S.T., Giri S.N. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 1999, 54:805-812.
33. Kolb M., Margetts P.J., Galt T., Sime P.J., Xing Z., Schmidt M., Gauldie J. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care Med. 2001, 163:770-777.
34. Li M., Krishnaveni M.S., Li C., Zhou B., Xing Y., Banfalvi A., Li A., Lombardi V., Akbari O., Borok Z., Minoo P. Epithelium-specific deletion of TGF-beta receptor type II protects mice from bleomycin-induced pulmonary fibrosis. J. Clin. Investig. 2011, 121:277-287.
35. Ask K., Bonniaud P., Maass K., Eickelberg O., Margetts P.J., Warburton D., Groffen J., Gauldie J., Kolb M. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int. J. Biochem. Cell Biol. 2008, 40:484-495.
36. Massague J., Seoane J., Wotton D. Smad transcription factors. Genes Dev. 2005, 19:2783-2810.
37. Rahimi R.A., Leof E.B. TGF-beta signaling: a tale of two responses. J. Cell. Biochem. 2007, 102:593-608.
38. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
39. Lan H.Y. Smad7 as a therapeutic agent for chronic kidney diseases. Front. Biosci. 2008, 13:4984-4992.
40. Corcoran J.B., McCarthy S., Griffin B., Gaffney A., Bhreathnach U., Borgeson E., Hickey F.B., Docherty N.G., Higgins D.F., Furlong F., Martin F., Godson C., Murphy M. IHG-1 must be localised to mitochondria to decrease Smad7 expression and amplify TGF-beta1-induced fibrotic responses. Biochim. Biophys. Acta 2013, 1833:1969-1978.
41. Dooley S., Delvoux B., Streckert M., Bonzel L., Stopa M., ten Dijke P., Gressner A.M. Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells. FEBS Lett. 2001, 502:4-10.
42. Schnabl B., Kweon Y.O., Frederick J.P., Wang X.F., Rippe R.A., Brenner D.A. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001, 34:89-100.
43. Lakos G., Takagawa S., Chen S.J., Ferreira A.M., Han G., Masuda K., Wang X.J., DiPietro L.A., Varga J. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am. J. Pathol. 2004, 165:203-217.
44. Fan D.L., Zhao W.J., Wang Y.X., Han S.Y., Guo S. Oxymatrine inhibits collagen synthesis in keloid fibroblasts via inhibition of transforming growth factor-beta1/Smad signaling pathway. Int. J. Dermatol. 2012, 51:463-472.
45. Kanasaki K., Koya D., Sugimoto T., Isono M., Kashiwagi A., Haneda M. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J. Am. Soc. Nephrol. 2003, 14:863-872.
46. Zhan M., Kanwar Y.S. Hierarchy of molecules in TGF-beta1 signaling relevant to myofibroblast activation and renal fibrosis. Am. J. Physiol. Ren. Physiol. 2014, 307:F385-F387.
47. Fernandez I.E., Eickelberg O. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc. Am. Thorac. Soc. 2012, 9:111-116.
48. Dooley S., Hamzavi J., Breitkopf K., Wiercinska E., Said H.M., Lorenzen J., Ten Dijke P., Gressner A.M. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003, 125:178-191.
49. Fukasawa H., Yamamoto T., Togawa A., Ohashi N., Fujigaki Y., Oda T., Uchida C., Kitagawa K., Hattori T., Suzuki S., Kitagawa M., Hishida A. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc. Natl. Acad. Sci. USA 2004, 101:8687-8692.
50. Biernacka A., Dobaczewski M., Frangogiannis N.G. TGF-beta signaling in fibrosis. Growth Factors 2011, 29:196-202.
51. Yu L., Hebert M.C., Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002, 21:3749-3759.
52. Stratton R., Rajkumar V., Ponticos M., Nichols B., Shiwen X., Black C.M., Abraham D.J., Leask A. Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J. 2002, 16:1949-1951.
53. Vayalil P.K., Iles K.E., Choi J., Yi A.K., Postlethwait E.M., Liu R.M. Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293:L1281-L1292.
54. Vayalil P.K., Olman M., Murphy-Ullrich J.E., Postlethwait E.M., Liu R.M. Glutathione restores collagen degradation in TGF-beta-treated fibroblasts by blocking plasminogen activator inhibitor-1 expression and activating plasminogen. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289:L937-L945.
55. Pannu J., Nakerakanti S., Smith E., ten Dijke P., Trojanowska M. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J. Biol. Chem. 2007, 282:10405-10413.
56. Yuan Q., Wang R., Peng Y., Fu X., Wang W., Wang L., Zhang F., Peng Z., Ning W., Hu G., Wang Z., Tao L. Fluorofenidone attenuates tubulointerstitial fibrosis by inhibiting TGF-beta(1)-induced fibroblast activation. Am. J. Nephrol. 2011, 34:181-194.
57. Lan R., Geng H., Polichnowski A.J., Singha P.K., Saikumar P., McEwen D.G., Griffin K.A., Koesters R., Weinberg J.M., Bidani A.K., Kriz W., Venkatachalam M.A. PTEN loss defines a TGF-beta-induced tubule phenotype of failed differentiation and JNK signaling during renal fibrosis. Am. J. Physiol. Ren. Physiol. 2012, 302:F1210-F1223.
58. Samarakoon R., Overstreet J.M., Higgins P.J. TGF-beta signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell. Signal. 2013, 25:264-268.
59. Jiang F., Liu G.S., Dusting G.J., Chan E.C. NADPH oxidase-dependent redox signaling in TGF-beta-mediated fibrotic responses. Redox Biol. 2014, 2:267-272.
60. Sampson N., Berger P., Zenzmaier C. Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic disease. Biomed. Res. Int. 2014, 2014:131737.
61. Manickam N., Patel M., Griendling K.K., Gorin Y., Barnes J.L. RhoA/Rho kinase mediates TGF-beta1-induced kidney myofibroblast activation through Poldip2/Nox4-derived reactive oxygen species. Am. J. Physiol. Ren. Physiol. 2014, 307:F159-F171.
62. Harvey K.A., Paranavitana C.N., Zaloga G.P., Siddiqui R.A. Diverse signaling pathways regulate fibroblast differentiation and transformation through Rho kinase activation. J. Cell. Physiol. 2007, 211:353-363.
63. Heasman S.J., Ridley A.J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 2008, 9:690-701.
64. Ridley A.J. Rho family proteins: coordinating cell responses. Trends Cell. Biol. 2001, 11:471-477.
65. Tsou P.S., Haak A.J., Khanna D., Neubig R.R. Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. Am. J. Physiol. Cell Physiol. 2014, 307:C2-13.
66. Zhou Y., Huang X., Hecker L., Kurundkar D., Kurundkar A., Liu H., Jin T.H., Desai L., Bernard K., Thannickal V.J. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J. Clin. Investig. 2013, 123:1096-1108.
67. Johnson L.A., Rodansky E.S., Haak A.J., Larsen S.D., Neubig R.R., Higgins P.D. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-beta-induced fibrogenesis in human colonic myofibroblasts. Inflamm. Bowel Dis. 2014, 20:154-165.
68. Jin L., Ying Z., Webb R.C. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H1495-H1500.
69. Bailey S.R., Mitra S., Flavahan S., Flavahan N.A. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H243-H250.
70. Heo J., Campbell S.L. Mechanism of redox-mediated guanine nucleotide exchange on redox-active Rho GTPases. J. Biol. Chem. 2005, 280:31003-31010.
71. Knock G.A., Snetkov V.A., Shaifta Y., Connolly M., Drndarski S., Noah A., Pourmahram G.E., Becker S., Aaronson P.I., Ward J.P. Superoxide constricts rat pulmonary arteries via Rho-kinase-mediated Ca(2+) sensitization. Free Radic. Biol. Med. 2009, 46:633-642.
72. Aghajanian A., Wittchen E.S., Campbell S.L., Burridge K. Direct activation of RhoA by reactive oxygen species requires a redox-sensitive motif. PloS One 2009, 4:e8045.
73. Soliman H., Gador A., Lu Y.H., Lin G., Bankar G., MacLeod K.M. Diabetes-induced increased oxidative stress in cardiomyocytes is sustained by a positive feedback loop involving Rho kinase and PKCbeta2. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H989-H1000.
74. Pernomian L., Santos Gomes M., Baraldi Araujo Restini C., Naira Zambelli Ramalho L., Renato Tirapelli C., Maria de Oliveira A. The role of reactive oxygen species in the modulation of the contraction induced by angiotensin II in carotid artery from diabetic rat. Eur. J. Pharmacol. 2012, 678:15-25.
75. Weidinger A., Kozlov A.V. Biological activities of reactive oxygen and nitrogen species: oxidative stress versus signal transduction. Biomolecules 2015, 5:472-484.
76. Herrera B., Alvarez A.M., Sanchez A., Fernandez M., Roncero C., Benito M., Fabregat I. Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor (beta) in fetal hepatocytes. FASEB J. 2001, 15:741-751.
77. Albright C.D., Salganik R.I., Craciunescu C.N., Mar M.H., Zeisel S.H. Mitochondrial and microsomal derived reactive oxygen species mediate apoptosis induced by transforming growth factor-beta1 in immortalized rat hepatocytes. J. Cell. Biochem. 2003, 89:254-261.
78. Herrera B., Murillo M.M., Alvarez-Barrientos A., Beltran J., Fernandez M., Fabregat I. Source of early reactive oxygen species in the apoptosis induced by transforming growth factor-[beta] in fetal rat hepatocytes. Free Radic. Biol. Med. 2004, 36:16-26.
79. Black D., Lyman S., Qian T., Lemasters J.J., Rippe R.A., Nitta T., Kim J.S., Behrns K.E. Transforming growth factor beta mediates hepatocyte apoptosis through Smad3 generation of reactive oxygen species. Biochimie 2007, 89:1464-1473.
80. Ortiz C., Caja L., Bertran E., Gonzalez-Rodriguez A., Valverde A.M., Fabregat I., Sancho P. Protein-tyrosine phosphatase 1B (PTP1B) deficiency confers resistance to transforming growth factor-beta (TGF-beta)-induced suppressor effects in hepatocytes. J. Biol. Chem. 2012, 287:15263-15274.
81. Yoon Y.S., Lee J.H., Hwang S.C., Choi K.S., Yoon G. TGF beta1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells. Oncogene 2005, 24:1895-1903.
82. Byun H.O., Jung H.J., Seo Y.H., Lee Y.K., Hwang S.C., Hwang E.S., Yoon G. GSK3 inactivation is involved in mitochondrial complex IV defect in transforming growth factor (TGF) beta1-induced senescence. Exp. Cell Res. 2012, 318:1808-1819.
83. Wu J., Niu J., Li X., Wang X., Guo Z., Zhang F. TGF-beta1 induces senescence of bone marrow mesenchymal stem cells via increase of mitochondrial ROS production. BMC Dev. Biol. 2014, 14:21.
84. Ishikawa F., Kaneko E., Sugimoto T., Ishijima T., Wakamatsu M., Yuasa A., Sampei R., Mori K., Nose K., Shibanuma M. A mitochondrial thioredoxin-sensitive mechanism regulates TGF-beta-mediated gene expression associated with epithelial-mesenchymal transition. Biochem. Biophys. Res. Commun. 2014, 443:821-827.
85. Jain M., Rivera S., Monclus E.A., Synenki L., Zirk A., Eisenbart J., Feghali-Bostwick C., Mutlu G.M., Budinger G.R., Chandel N.S. Mitochondrial reactive oxygen species regulate transforming growth factor-beta signaling. J. Biol. Chem. 2013, 288:770-777.
86. Bracey N.A., Gershkovich B., Chun J., Vilaysane A., Meijndert H.C., Wright J.R., Fedak P.W., Beck P.L., Muruve D.A., Duff H.J. Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad protein signaling and fibrosis independent from the inflammasome. J. Biol. Chem. 2014, 289:19571-19584.
87. Abe Y., Sakairi T., Beeson C., Kopp J.B. TGF-beta1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway. Am. J. Physiol. Ren. Physiol. 2013, 305:F1477-F1490.
88. Hagler M.A., Hadley T.M., Zhang H., Mehra K., Roos C.M., Schaff H.V., Suri R.M., Miller J.D. TGF-beta signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves. Cardiovasc. Res. 2013, 99:175-184.
89. Pociask D.A., Sime P.J., Brody A.R. Asbestos-derived reactive oxygen species activate TGF-beta1. Lab. Investig. 2004, 84:1013-1023.
90. Kim Y.M., Cho M. Activation of NADPH oxidase subunit NCF4 induces ROS-mediated EMT signaling in HeLa cells. Cell. Signal. 2014, 26:784-796.
91. Sancho P., Bertran E., Caja L., Carmona-Cuenca I., Murillo M.M., Fabregat I. The inhibition of the epidermal growth factor (EGF) pathway enhances TGF-beta-induced apoptosis in rat hepatoma cells through inducing oxidative stress coincident with a change in the expression pattern of the NADPH oxidases (NOX) isoforms. Biochim. Biophys. Acta 2009, 1793:253-263.
92. Bondi C.D., Manickam N., Lee D.Y., Block K., Gorin Y., Abboud H.E., Barnes J.L. NAD(P)H oxidase mediates TGF-{beta}1-induced activation of kidney myofibroblasts. J. Am. Soc. Nephrol. 2010, 21:93-102.
93. Sturrock A., Cahill B., Norman K., Huecksteadt T.P., Hill K., Sanders K., Karwande S.V., Stringham J.C., Bull D.A., Gleich M., Kennedy T.P., Hoidal J.R. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290:L661-L673.
94. Sturrock A., Huecksteadt T.P., Norman K., Sanders K., Murphy T.M., Chitano P., Wilson K., Hoidal J.R., Kennedy T.P. Nox4 mediates TGF-beta1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in human airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292:L1543-L1555.
95. Ismail S., Sturrock A., Wu P., Cahill B., Norman K., Huecksteadt T., Sanders K., Kennedy T., Hoidal J. NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296:L489-L499.
96. Cucoranu I., Clempus R., Dikalova A., Phelan P.J., Ariyan S., Dikalov S., Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ. Res. 2005, 97:900-907.
97. Murillo M.M., Carmona-Cuenca I., Del Castillo G., Ortiz C., Roncero C., Sanchez A., Fernandez M., Fabregat I. Activation of NADPH oxidase by transforming growth factor-beta in hepatocytes mediates up-regulation of epidermal growth factor receptor ligands through a nuclear factor-kappaB-dependent mechanism. Biochem. J. 2007, 405:251-259.
98. Carmona-Cuenca I., Roncero C., Sancho P., Caja L., Fausto N., Fernandez M., Fabregat I. Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J. Hepatol. 2008, 49:965-976.
99. Hu T., RamachandraRao S.P., Siva S., Valancius C., Zhu Y., Mahadev K., Toh I., Goldstein B.J., Woolkalis M., Sharma K. Reactive oxygen species production via NADPH oxidase mediates TGF-{beta}-induced cytoskeletal alterations in endothelial cells. Am. J. Physiol. Ren. Physiol. 2005, 289:F816-F825.
100. Liu R.M., Choi J., Wu J.H., Gaston Pravia K.A., Lewis K.M., Brand J.D., Mochel N.S., Krzywanski D.M., Lambeth J.D., Hagood J.S., Forman H.J., Thannickal V.J., Postlethwait E.M. Oxidative modification of nuclear mitogen-activated protein kinase phosphatase 1 is involved in transforming growth factor beta1-induced expression of plasminogen activator inhibitor 1 in fibroblasts. J. Biol. Chem. 2010, 285:16239-16247.
101. Boudreau H.E., Casterline B.W., Rada B., Korzeniowska A., Leto T.L. Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic. Biol. Med. 2012, 53:1489-1499.
102. Buul J.D.V., Fernandez-Borja M., Anthony E.C., Hordijk P.L. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid. Redox Signal. 2005, 7:308.
103. Chen K., Kirber M.T., Xiao H., Yang Y., Keaney J.F. Regulation of ROS signal transduction by NADPH oxidase 4 localization. J. Cell Biol. 2008, 181:1129-1139.
104. Helmcke I., Heumuller S., Tikkanen R., Schroder K., Brandes R.P. Identification of structural elements in Nox1 and Nox4 controlling localization and activity. Antioxid. Redox Signal. 2009, 11:1279-1287.
105. Mittal M., Roth M., Konig P., Hofmann S., Dony E., Goyal P., Selbitz A.-C., Schermuly R.T., Ghofrani H.A., Kwapiszewska G., Kummer W., Klepetko W., Hoda M.A.R., Fink L., Hanze J., Seeger W., Grimminger F., Schmidt H.H.H.W., Weissmann N. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ. Res. 2007, 101:258-267.
106. Kuroda Junya, Nakagawa K., Yamasaki Tomoko, Nakamura Kei-ichiro, Takeya Ryu, Kuribayashi Futoshi, Imajoh-Ohmi Shinobu, Igarashi Kazuhiko, Shibata Yosaburo, Sueishi Katsuo, Sumimoto Hideki The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells 2005, 10:1139-1151.
107. Case A.J., Li S., Basu U., Tian J., Zimmerman M.C. Mitochondrial-localized NADPH oxidase 4 is a source of superoxide in angiotensin II-stimulated neurons. Am. J. Physiol. Heart Circ. Physiol. 2013, 305:H19-H28.
108. Block K., Gorin Y., Abboud H.E. Subcellular localization of Nox4 and regulation in diabetes. Proc. Natl. Acad. Sci. USA 2009, 106:14385-14390.
109. Kim S.M., Kim Y.G., Jeong K.H., Lee S.H., Lee T.W., Ihm C.G., Moon J.Y. Angiotensin II-induced mitochondrial Nox4 is a major endogenous source of oxidative stress in kidney tubular cells. PloS One 2012, 7:e39739.
110. Casalena G., Daehn I., Bottinger E. Transforming growth factor-beta, bioenergetics, and mitochondria in renal disease. Semin. Nephrol. 2012, 32:295-303.
111. Hecker L., Vittal R., Jones T., Jagirdar R., Luckhardt T.R., Horowitz J.C., Pennathur S., Martinez F.J., Thannickal V.J. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 2009, 15:1077-1081.
112. Tobar N., Toyos M., Urra C., Mendez N., Arancibia R., Smith P.C., Martinez J. c-Jun N terminal kinase modulates NOX-4 derived ROS production and myofibroblasts differentiation in human breast stromal cells. BMC Cancer 2014, 14:640.
113. Yan F., Wang Y., Wu X., Peshavariya H.M., Dusting G.J., Zhang M., Jiang F. Nox4 and redox signaling mediate TGF-beta-induced endothelial cell apoptosis and phenotypic switch. Cell Death Dis. 2014, 5:e1010.
114. Caja L., Sancho P., Bertran E., Iglesias-Serret D., Gil J., Fabregat I. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res. 2009, 69:7595-7602.
115. Chan E.C., Peshavariya H.M., Liu G.S., Jiang F., Lim S.Y., Dusting G.J. Nox4 modulates collagen production stimulated by transforming growth factor beta1 in vivo and in vitro. Biochem. Biophys. Res. Commun. 2013, 430:918-925.
116. Amara N., Goven D., Prost F., Muloway R., Crestani B., Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 2010, 65:733-738.
117. Hecker L., Logsdon N.J., Kurundkar D., Kurundkar A., Bernard K., Hock T., Meldrum E., Sanders Y.Y., Thannickal V.J. Reversal of persistent fibrosis in aging by targeting nox4-nrf2 redox imbalance. Sci. Transl. Med. 2014, 6:231ra247.
118. Jiang J.X., Chen X., Serizawa N., Szyndralewiez C., Page P., Schroder K., Brandes R.P., Devaraj S., Torok N.J. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic. Biol. Med. 2012, 53:289-296.
119. Michaeloudes C., Sukkar M.B., Khorasani N.M., Bhavsar P.K., Chung K.F. TGF-beta regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300:L295-L304.
120. Yeh Y.H., Kuo C.T., Chang G.J., Qi X.Y., Nattel S., Chen W.J. Nicotinamide adenine dinucleotide phosphate oxidase 4 mediates the differential responsiveness of atrial versus ventricular fibroblasts to transforming growth factor-beta. Circ. Arrhythm. Electrophysiol. 2013, 6:790-798.
121. Rathore R., Zheng Y.M., Niu C.F., Liu Q.H., Korde A., Ho Y.S., Wang Y.X. Hypoxia activates NADPH oxidase to increase [ROS]i and [Ca2+]i through the mitochondrial ROS-PKCepsilon signaling axis in pulmonary artery smooth muscle cells. Free Radic. Biol. Med. 2008, 45:1223-1231.
122. Wosniak J., Santos C.X., Kowaltowski A.J., Laurindo F.R. Cross-talk between mitochondria and NADPH oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells. Antioxid. Redox Signal. 2009, 11:1265-1278.
123. Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim. Biophys. Acta 2010, 1797:897-906.
124. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic. Biol. Med. 2011, 51:1289-1301.
125. Vendrov A.E., Vendrov K.C., Smith A., Yuan J., Sumida A., Robidoux J., Runge M.S., Madamanchi N.R. NOX4 NADPH oxidase-dependent mitochondrial oxidative stress in aging-associated cardiovascular disease. Antioxid. Redox Signal. 2015.
126. Roum J.H., Buhl R., McElvany N.G., Borok Z., Crystal R.G. Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 1993, 75:2419-2424.
127. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., Moss R.B. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc. Natl. Acad. Sci. USA 2006, 103:4628-4633.
128. Rahman I., Skwarska E., Henry M., Davis M., O'Connor C.M., FitzGerald M.X., Greening A., MacNee W. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 1999, 27:60-68.
129. Pacht E.R., Timerman A.P., Lykens M.G., Merola A.J. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 1991, 100:1397-1403.
130. Bunnell E., Pacht E.R. Oxidized glutathione is increased in the alveolar fluid of patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1993, 148:1174-1178.
131. Laurent T., Markert M., Feihl F., Schaller M.D., Perret C. Oxidant-antioxidant balance in granulocytes during ARDS. Effect of N-acetylcysteine. Chest 1996, 109:163-166.
132. Bernard G.R., Wheeler A.P., Arons M.M., Morris P.E., Paz H.L., Russell J.A., Wright P.E. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest 1997, 112:164-172.
133. Soltan-Sharifi M.S., Mojtahedzadeh M., Najafi A., Reza Khajavi M., Reza Rouini M., Moradi M., Mohammadirad A., Abdollahi M. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Hum. Exp. Toxicol. 2007, 26:697-703.
134. Borok Z., Grimes G.J., Buhl R., Bokser A., Hubbard R.C., Holroyd K., Roum J.H., Czerski D.B., Cantin A.M., Crystal R.G. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991, 338:215-216.
135. Meyer A., Buhl R., Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 1994, 7:431-436.
136. Behr J., Maier K., Degenkolb B., Krombach F., Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. 1997, 156:1897-1901.
137. Behr J., Degenkolb B., Krombach F., Vogelmeier C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur. Respir. J. 2002, 19:906-911.
138. Montaldo C., Cannas E., Ledda M., Rosetti L., Congiu L., Atzori L. Bronchoalveolar glutathione and nitrite/nitrate in idiopathic pulmonary fibrosis and sarcoidosis. Sarcoidosis Vasc. Diffus. Lung Dis. 2002, 19:54-58.
139. Beeh K.M., Beier J., Haas I.C., Kornmann O., Micke P., Buhl R. Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2002, 19:1119-1123.
140. Tiitto L.H., Peltoniemi M.J., Kaarteenaho-Wiik R.L., Soini Y.M., Paakko P.K., Sormunen R.T., Kinnula V.L. Cell-specific regulation of gamma-glutamylcysteine synthetase in human interstitial lung diseases. Hum. Pathol. 2004, 35:832-839.
141. Boots A.W., Drent M., Swennen E.L.R., Moonen H.J.J., Bast A., Haenen G.R.M.M. Antioxidant status associated with inflammation in sarcoidosis: a potential role for antioxidants. Respir. Med. 2009, 103:364-372.
142. Bianchi G., Bugianesi E., Ronchi M., Fabbri A., Zoli M., Marchesini G. Glutathione kinetics in normal man and in patients with liver cirrhosis. J. Hepatol. 1997, 26:606-613.
143. Aboutwerat A., Pemberton P.W., Smith A., Burrows P.C., McMahon R.F.T., Jain S.K., Warnes T.W. Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim. Et. Biophys. Acta - Mol. Basis Dis. 1637, 142-150:2003.
144. Loguercio C., Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic. Biol. Med. 2003, 34:1-10.
145. Czeczot H., Scibior D., Skrzycki M., Podsiad M. Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochim. Pol. 2006, 53:237-242.
146. Priyanka Bandara J.G., Geoffrey Mc.Caughan, Daya Naidoo, Ora Lux, Chris Salonikas, Kench James, Byth Karen, Geoffrey C.Farrell Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver Int. 2005, 25:518-526.
147. Marotta F., Yoshida C., Barreto R., Naito Y., Packer L. Oxidative-inflammatory damage in cirrhosis: effect of vitamin E and a fermented papaya preparation. J. Gastroenterol. Hepatol. 2007, 22:697-703.
148. Osman H., Gabr O., Lotfy S., Gabr S. Serum levels of bcl-2 and cellular oxidative stress in patients with viral hepatitis. Indian J. Med. Microbiol. 2007, 25:323-329.
149. Ma J.Y., Barger M.W., Hubbs A.F., Castranova V., Weber S.L., Ma J.K. Use of tetrandrine to differentiate between mechanisms involved in silica-versus bleomycin-induced fibrosis. J. Toxicol. Environ. Healh A 1999, 57:247-266.
150. Candan F., Alagozlu H. Captopril inhibits the pulmonary toxicity of paraquat in rats. Hum. Exp. Toxicol. 2001, 20:637-641.
151. Arslan S.O., Zerin M., Vural H., Coskun A. The effect of melatonin on bleomycin-induced pulmonary fibrosis in rats. J. Pineal Res. 2002, 32:21-25.
152. Nieto N., Cederbaum A.I. S-adenosylmethionine blocks collagen I production by preventing transforming growth factor-{beta} induction of the COL1A2 promoter. J. Biol. Chem. 2005, 280:30963-30974.
153. Iyer S.S., Ramirez A.M., Ritzenthaler J.D., Torres-Gonzalez E., Roser-Page S., Mora A.L., Brigham K.L., Jones D.P., Roman J., Rojas M. Oxidation of extracellular cysteine/cystine redox state in bleomycin-induced lung fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296:L37-L45.
154. Atzori L., Chua F., Dunsmore S.E., Willis D., Barbarisi M., McAnulty R.J., Laurent G.J. Attenuation of bleomycin induced pulmonary fibrosis in mice using the heme oxygenase inhibitor Zn-deuteroporphyrin IX-2,4-bisethylene glycol. Thorax 2004, 59:217-223.
155. El-Medany A., Hagar H.H., Moursi M., At Muhammed R., El-Rakhawy F.I., El-Medany G. Attenuation of bleomycin-induced lung fibrosis in rats by mesna. Eur. J. Pharmacol. 2005, 509:61-70.
156. Boyaci H., Maral H., Turan G., Başyiğit I, Dillioğlugil M., Yildiz F., Tugay M., Pala A., Erçin C. Effects of erdosteine on bleomycin-induced lung fibrosis in rats. Mol. Cell. Biochem. 2006, 281:129-137.
157. Deger Yeter, Yur F., Ertekin Ali, Mert Nihat, Dede Semiha, Mert Handan Protective effect of alpha-tocopherol on oxidative stress in experimental pulmonary fibrosis in rats. Cell Biochem. Funct. 2007, 25:633-637.
158. Arafa H.M.M., Abdel-Wahab M.H., El-Shafeey M.F., Badary O.A., Hamada F.M.A. Anti-fibrotic effect of meloxicam in a murine lung fibrosis model. Eur. J. Pharmacol. 2007, 564:181-189.
159. White A.C., Das S.K., Fanburg B.L. Reduction of glutathione is associated with growth restriction and enlargement of bovine pulmonary artery endothelial cells produced by transforming growth factor-beta 1. Am. J. Respir. Cell Mol. Biol. 1992, 6:364-368.
160. Sanchez A., Alvarez A.M., Benito M., Fabregat I. Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates. J. Biol. Chem. 1996, 271:7416-7422.
161. Sanchez A., Alvarez A.M., Benito M., Fabregat I. Cycloheximide prevents apoptosis, reactive oxygen species production, and glutathione depletion induced by transforming growth factor beta in fetal rat hepatocytes in primary culture. Hepatology 1997, 26:935-943.
162. Arsalane K., Dubois C.M., Muanza T., Begin R., Boudreau F., Asselin C., Cantin A.M. Transforming growth factor-beta1 is a potent inhibitor of glutathione synthesis in the lung epithelial cell line A549: transcriptional effect on the GSH rate-limiting enzyme gamma-glutamylcysteine synthetase. Am. J. Respir. Cell Mol. Biol. 1997, 17:599-607.
163. Pittet J.F., Griffiths M.J., Geiser T., Kaminski N., Dalton S.L., Huang X., Brown L.A., Gotwals P.J., Koteliansky V.E., Matthay M.A., Sheppard D. TGF-beta is a critical mediator of acute lung injury. J. Clin. Invest. 2001, 107:1537-1544.
164. Jardine H., MacNee W., Donaldson K., Rahman I. Molecular mechanism of transforming growth factor (TGF)-beta1-induced glutathione depletion in alveolar epithelial cells. Involvement of AP-1/ARE and Fra-1. J. Biol. Chem. 2002, 277:21158-21166.
165. Franklin C.C., Rosenfeld-Franklin M.E., White C., Kavanagh T.J., Fausto N. TGFbeta1-induced suppression of glutathione antioxidant defenses in hepatocytes: caspase-dependent post-translational and caspase-independent transcriptional regulatory mechanisms. FASEB J. 2003, 17:1535-1537.
166. Herrera B., Murillo M.M., Alvarez-Barrientos A., Beltran J., Fernandez M., Fabregat I. Source of early reactive oxygen species in the apoptosis induced by transforming growth factor-beta in fetal rat hepatocytes. Free Radic. Biol. Med. 2004, 36:16-26.
167. Bakin A.V., Stourman N.V., Sekhar K.R., Rinehart C., Yan X., Meredith M.J., Arteaga C.L., Freeman M.L. Smad3-ATF3 signaling mediates TGF-[beta] suppression of genes encoding Phase II detoxifying proteins. Free Radic. Biol. Med. 2005, 38:375-387.
168. Liu R.-M., Liu Y., Forman H.J., Olman M., Tarpey M.M. Glutathione regulates transforming growth factor-{beta}-stimulated collagen production in fibroblasts. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L121-L128.
169. McKone E.F., Shao J., Frangolias D.D., Keener C.L., Shephard C.A., Farin F.M., Tonelli M.R., Pare P.D., Sandford A.J., Aitken M.L., Kavanagh T.J. Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 2006, 174:415-419.
170. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 2001, 30:1191-1212.
171. Dayer R., Fischer B.B., Eggen R.I., Lemaire S.D. The peroxiredoxin and glutathione peroxidase families in Chlamydomonas reinhardtii. Genetics 2008, 179:41-57.
172. Kayanoki Y., Fujii J., Suzuki K., Kawata S., Matsuzawa Y., Taniguchi N. Suppression of antioxidative enzyme expression by transforming growth factor-beta 1 in rat hepatocytes. J. Biol. Chem. 1994, 269:15488-15492.
173. Islam K.N., Kayanoki Y., Kaneto H., Suzuki K., Asahi M., Fujii J., Taniguchi N. TGF-beta1 triggers oxidative modifications and enhances apoptosis in HIT cells through accumulation of reactive oxygen species by suppression of catalase and glutathione peroxidase. Free Radic. Biol. Med. 1997, 22:1007-1017.
174. Peltoniemi M., Kaarteenaho-Wiik R., Saily M., Sormunen R., Paakko P., Holmgren A., Soini Y., Kinnula V.L. Expression of glutaredoxin is highly cell specific in human lung and is decreased by transforming growth factor-beta in vitro and in interstitial lung diseases in vivo. Hum. Pathol. 2004, 35:1000-1007.
175. Gao F., Kinnula V.L., Myllarniemi M., Oury T.D. Extracellular superoxide dismutase in pulmonary fibrosis. Antioxid. Redox Signal. 2008, 10:343-354.
176. Cui Y., Robertson J., Maharaj S., Waldhauser L., Niu J., Wang J., Farkas L., Kolb M., Gauldie J. Oxidative stress contributes to the induction and persistence of TGF-beta1 induced pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2011, 43:1122-1133.
177. Saharinen J., Taipale J., Monni O., Keski-Oja J. Identification and characterization of a new latent transforming growth factor-beta -binding protein, LTBP-4. J. Biol. Chem. 1998, 273:18459-18469.
178. Todorovic V., Jurukovski V., Chen Y., Fontana L., Dabovic B., Rifkin D.B. Latent TGF-[beta] binding proteins. Int. J. Biochem. Cell Biol. 2005, 37:38-41.
179. Schultz-Cherry S., Murphy-Ullrich J.E. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J. Cell Biol. 1993, 122:923-932.
180. Murphy-Ullrich J.E., Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000, 11:59-69.
181. Munger J.S., Huang X., Kawakatsu H., Griffiths M.J., Dalton S.L., Wu J., Pittet J.F., Kaminski N., Garat C., Matthay M.A., Rifkin D.B., Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999, 96:319-328.
182. Mu D., Cambier S., Fjellbirkeland L., Baron J.L., Munger J.S., Kawakatsu H., Sheppard D., Broaddus V.C., Nishimura S.L. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J. Cell Biol. 2002, 157:493-507.
183. Lyons R.M., Keski-Oja J., Moses H.L. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J. Cell Biol. 1988, 106:1659-1665.
184. Taipale J., Lohi J., Saarinen J., Kovanen P.T., Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem. 1995, 270:4689-4696.
185. Taipale J., Koli K., Keski-Oja J. Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J. Biol. Chem. 1992, 267:25378-25384.
186. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14:163-176.
187. Barcellos-Hoff M., Dix T. Redox-mediated activation of latent transforming growth factor-beta 1. Mol. Endocrinol. 1996, 10:1077-1083.
188. Vodovotz Y., Chesler L., Chong H., Kim S.J., Simpson J.T., DeGraff W., Cox G.W., Roberts A.B., Wink D.A., Barcellos-Hoff M.H. Regulation of transforming growth factor beta1 by nitric oxide. Cancer Res. 1999, 59:2142-2149.
189. Wang L., Clutter S., Benincosa J., Fortney J., Gibson L.F. Activation of TGF-{beta}1/p38/Smad3 signaling in stromal cells requires ROS-mediated MMP-2 activity during bone marrow damage. Stem Cells 2005, 23:1122-1134.
190. Amarnath S., Dong L., Li J., Wu Y., Chen W. Endogenous TGF-beta activation by reactive oxygen species is key to Foxp3 induction in TCR-stimulated and HIV-1-infected human CD4+CD25- T cells. Retrovirology 2007, 4:57.
191. Koli K., Myllarniemi M., Keski-Oja J., Kinnula V.L. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid. Redox Signal. 2008, 10:333-342.
192. Sullivan D.E., Ferris M., Pociask D., Brody A.R. The latent form of TGFbeta(1) is induced by TNFalpha through an ERK specific pathway and is activated by asbestos-derived reactive oxygen species in vitro and in vivo. J. Immunotoxicol. 2008, 5:145-149.
193. Jobling M.F., Mott J.D., Finnegan M.T., Jurukovski V., Erickson A.C., Walian P.J., Taylor S.E., Ledbetter S., Lawrence C.M., Rifkin D.B., Barcellos-Hoff M.H. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat. Res. 2006, 166:839-848.
194. Saito K., Ishizaka N., Aizawa T., Sata M., Iso-o N., Noiri E., Mori I., Ohno M., Nagai R. Iron chelation and a free radical scavenger suppress angiotensin II-induced upregulation of TGF-beta1 in the heart. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H1836-H1843.
195. Zhao W., Zhao T., Chen Y., Ahokas R.A., Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol. Cell. Biochem. 2008, 317:43-50.
196. Shvedova A.A., Kisin E.R., Murray A.R., Kommineni C., Castranova V., Fadeel B., Kagan V.E. Increased accumulation of neutrophils and decreased fibrosis in the lung of NADPH oxidase-deficient C57BL/6 mice exposed to carbon nanotubes. Toxicol. Appl. Pharmacol. 2008, 231:235-240.
197. Lin W., Tsai W.L., Shao R.X., Wu G., Peng L.F., Barlow L.L., Chung W.J., Zhang L., Zhao H., Jang J.Y., Chung R.T. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 2010, 138:2509-2518. 2518. e1.
198. Jaffer O.A., Carter A.B., Sanders P.N., Dibbern M.E., Winters C.J., Murthy S., Ryan A.J., Rokita A.G., Prasad A.M., Zabner J., Kline J.N., Grumbach I.M., Anderson M.E. Mitochondrial-targeted antioxidant therapy decreases transforming growth factor-beta-mediated collagen production in a murine asthma model. Am. J. Respir. Cell Mol. Biol. 2015, 52:106-115.
199. Montorfano I., Becerra A., Cerro R., Echeverria C., Saez E., Morales M.G., Fernandez R., Cabello-Verrugio C., Simon F. Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-beta1 and TGF-beta2-dependent pathway. Lab. Invest. 2014, 94:1068-1082.
200. Oruqaj G., Karnati S., Vijayan V., Kotarkonda L.K., Boateng E., Zhang W., Ruppert C., Gunther A., Shi W., Baumgart-Vogt E. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-beta signaling. Proc. Natl. Acad. Sci. USA 2015, 112:E2048-E2057.
201. Bellocq A., Azoulay E., Marullo S., Flahault A., Fouqueray B., Philippe C., Cadranel J., Baud L. Reactive oxygen and nitrogen intermediates increase transforming growth factor-beta1 release from human epithelial alveolar cells through two different mechanisms. Am. J. Respir. Cell Mol. Biol. 1999, 21:128-136.
202. Moon Y.M., Kang H.J., Cho J.S., Park I.H., Lee H.M. Nox4 mediates hypoxia-stimulated myofibroblast differentiation in nasal polyp-derived fibroblasts. Int. Arch. Allergy Immunol. 2012, 159:399-409.
203. Sancho P., Mainez J., Crosas-Molist E., Roncero C., Fernandez-Rodriguez C.M., Pinedo F., Huber H., Eferl R., Mikulits W., Fabregat I. NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PloS One 2012, 7:e45285.
204. Aoyama T., Paik Y.H., Watanabe S., Laleu B., Gaggini F., Fioraso-Cartier L., Molango S., Heitz F., Merlot C., Szyndralewiez C., Page P., Brenner D.A. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 2012, 56:2316-2327.
205. Maher T.M., Evans I.C., Bottoms S.E., Mercer P.F., Thorley A.J., Nicholson A.G., Laurent G.J., Tetley T.D., Chambers R.C., McAnulty R.J. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2010, 182:73-82.
206. Buhling F., Wille A., Rocken C., Wiesner O., Baier A., Meinecke I., Welte T., Pap T. Altered expression of membrane-bound and soluble CD95/Fas contributes to the resistance of fibrotic lung fibroblasts to FasL induced apoptosis. Respir. Res 2005, 6:37.
207. Huang W.T., Akhter H., Jiang C., MacEwen M., Ding Q., Antony V., Thannickal V.J., Liu R.M. Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis. Exp. Gerontol. 2015, 61:62-75.
208. Barbas-Filho J.V., Ferreira M.A., Sesso A., Kairalla R.A., Carvalho C.R., Capelozzi V.L. Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J. Clin. Pathol. 2001, 54:132-138.
209. Plataki M., Koutsopoulos A.V., Darivianaki K., Delides G., Siafakas N.M., Bouros D. Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 2005, 127:266-274.
210. Gunther A., Korfei M., Mahavadi P., von der Beck D., Ruppert C., Markart P. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur. Respir. Rev.: Off. J. Eur. Respir. Soc. 2012, 21:152-160.
211. Moodley Y.P., Caterina P., Scaffidi A.K., Misso N.L., Papadimitriou J.M., McAnulty R.J., Laurent G.J., Thompson P.J., Knight D.A. Comparison of the morphological and biochemical changes in normal human lung fibroblasts and fibroblasts derived from lungs of patients with idiopathic pulmonary fibrosis during FasL-induced apoptosis. J. Pathol. 2004, 202:486-495.
212. Hagimoto N., Kuwano K., Nomoto Y., Kunitake R., Hara N. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Cell. Mol. Biol. 1997, 16:91-101.
213. Budinger G.R., Mutlu G.M., Eisenbart J., Fuller A.C., Bellmeyer A.A., Baker C.M., Wilson M., Ridge K., Barrett T.A., Lee V.Y., Chandel N.S. Proapoptotic Bid is required for pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 2006, 103:4604-4609.
214. Degryse A.L., Tanjore H., Xu X.C., Polosukhin V.V., Jones B.R., McMahon F.B., Gleaves L.A., Blackwell T.S., Lawson W.E. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299:L442-L452.
215. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 2002, 110:341-350.
216. Slattery C., Campbell E., McMorrow T., Ryan M.P. Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am. J. Pathol. 2005, 167:395-407.
217. Saika S., Kono-Saika S., Ohnishi Y., Sato M., Muragaki Y., Ooshima A., Flanders K.C., Yoo J., Anzano M., Liu C.Y., Kao W.W., Roberts A.B. Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury. Am. J. Pathol. 2004, 164:651-663.
218. Margetts P.J., Bonniaud P., Liu L., Hoff C.M., Holmes C.J., West-Mays J.A., Kelly M.M. Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J. Am. Soc. Nephrol. 2005, 16:425-436.
219. Kim K.K., Kugler M.C., Wolters P.J., Robillard L., Galvez M.G., Brumwell A.N., Sheppard D., Chapman H.A. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. USA 2006, 103:13180-13185.
220. Wu Z., Yang L., Cai L., Zhang M., Cheng X., Yang X., Xu J. Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an alpha-smooth muscle actin-Cre transgenic mouse. Respir. Res 2007, 8:1.
221. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
222. Chapman H.A. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu. Rev. Physiol. 2011, 73:413-435.
223. Marmai C., Sutherland R.E., Kim K.K., Dolganov G.M., Fang X., Kim S.S., Jiang S., Golden J.A., Hoopes C.W., Matthay M.A., Chapman H.A., Wolters P.J. Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 2011, 301:L71-L78.
224. Flier S.N., Tanjore H., Kokkotou E.G., Sugimoto H., Zeisberg M., Kalluri R. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J. Biol. Chem. 2010, 285:20202-20212.
225. Tanjore H., Xu X.C., Polosukhin V.V., Degryse A.L., Li B., Han W., Sherrill T.P., Plieth D., Neilson E.G., Blackwell T.S., Lawson W.E. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am. J. Respir. Crit. Care Med. 2009, 180:657-665.
226. LeBleu V.S., Taduri G., O'Connell J., Teng Y., Cooke V.G., Woda C., Sugimoto H., Kalluri R. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 2013, 19:1047-1053.
227. Jain R., Shaul P.W., Borok Z., Willis B.C. Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am. J. Respir. Cell Mol. Biol. 2007, 37:38-47.
228. Rhyu D.Y., Yang Y., Ha H., Lee G.T., Song J.S., Uh S.T., Lee H.B. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J. Am. Soc. Nephrol. 2005, 16:667-675.
229. Lee E.K., Jeon W.K., Chae M.Y., Hong H.Y., Lee Y.S., Kim J.H., Kwon J.Y., Kim B.C., Park S.H. Decreased expression of glutaredoxin 1 is required for transforming growth factor-beta1-mediated epithelial-mesenchymal transition of EpRas mammary epithelial cells. Biochem. Biophys. Res. Commun. 2010, 391:1021-1027.
230. Zhou Q., Yang M., Lan H., Yu X. miR-30a negatively regulates TGF-beta1-induced epithelial-mesenchymal transition and peritoneal fibrosis by targeting Snai1. Am. J. Pathol. 2013, 183:808-819.
231. Derynck R., Muthusamy B.P., Saeteurn K.Y. Signaling pathway cooperation in TGF-beta-induced epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 2014, 31:56-66.
232. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell. Biol. 2014, 15:178-196.
233. Hiraga R., Kato M., Miyagawa S., Kamata T., Nox4-derived R.O.S. signaling contributes to TGF-beta-induced epithelial-mesenchymal transition in pancreatic cancer cells. Anticancer Res. 2013, 33:4431-4438.
234. Felton V.M., Borok Z., Willis B.C. N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 297:L805-L812.
235. Zhou G., Dada L.A., Wu M., Kelly A., Trejo H., Zhou Q., Varga J., Sznajder J.I. Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 297:L1120-L1130.
236. Lee J.H., Kim J.H., Kim J.S., Chang J.W., Kim S.B., Park J.S., Lee S.K. AMP-activated protein kinase inhibits TGF-beta-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. Am. J. Physiol. Ren. Physiol. 2013, 304:F686-F697.
237. Liu X.X., Zhou H.J., Cai L., Zhang W., Ma J.L., Tao X.J., Yu J.N. NADPH oxidase-dependent formation of reactive oxygen species contributes to transforming growth factor beta1-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells, and the role of astragalus intervention. Chin. J. Integr. Med. 2014, 20:667-674.
238. Lardot C., Heusterpreute M., Mertens P., Philippe M., Lison D. Expression of plasminogen activator inhibitors type-1 and type-2 in the mouse lung after administration of crystalline silica. Eur. Respir. J. 1998, 11:912-921.
239. El Solh A.A., Bhora M., Pineda L., Aquilina A., Abbetessa L., Berbary E. Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis. Intensive Care Med. 2006, 32:110-115.
240. Idell S., Koenig K.B., Fair D.S., Martin T.R., McLarty J., Maunder R.J. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am. J. Physiol. Lung Cell. Mol. Physiol. 1991, 261:L240-L248.
241. Kotani I., Sato A., Hayakawa H., Urano T., Takada Y., Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb. Res. 1995, 77:493-504.
242. Senoo T., Hattori N., Tanimoto T., Furonaka M., Ishikawa N., Fujitaka K., Haruta Y., Murai H., Yokoyama A., Kohno N. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010, 65:334-340.
243. Chang W., Wei K., Jacobs S.S., Upadhyay D., Weill D., Rosen G.D. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J. Biol. Chem. 2010, 285:8196-8206.
244. Olman M.A., Mackman N., Gladson C.L., Moser K.M., Loskutoff D.J. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J. Clin. Investig. 1995, 96:1621-1630.
245. Zhang Y., Ma J. Changes of coagulation and fibrinolysis systen in bronchoalveolar lavage fluid in lung fibrosis. Beijing Da Xue Xue Bao 2005, 37:516-519.
246. Eitzman D.T., McCoy R.D., Zheng X., Fay W.P., Shen T., Ginsburg D., Simon R.H. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Investig. 1996, 97:232-237.
247. Hattori N., Degen J.L., Sisson T.H., Liu H., Moore B.B., Pandrangi R.G., Simon R.H., Drew A.F. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J. Clin. Invest. 2000, 106:1341-1350.
248. Chuang-Tsai S., Sisson T.H., Hattori N., Tsai C.G., Subbotina N.M., Hanson K.E., Simon R.H. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am. J. Pathol. 2003, 163:445-452.
249. Samarakoon R., Higgins C.E., Higgins S.P., Kutz S.M., Higgins P.J. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent. J. Cell. Physiol. 2005, 204:236-246.
250. Guo B., Inoki K., Isono M., Mori H., Kanasaki K., Sugimoto T., Akiba S., Sato T., Yang B., Kikkawa R., Kashiwagi A., Haneda M., Koya D. MAPK//AP-1-dependent regulation of PAI-1 gene expression by TGF-[beta] in rat mesangial cells. Kidney Int. 2005, 68:972-984.
251. Yang C., Patel K., Harding P., Sorokin A., Glass W.F. Regulation of TGF-[beta]1/MAPK-mediated PAI-1 gene expression by the actin cytoskeleton in human mesangial cells. Exp. Cell Res. 2007, 313:1240-1250.
252. Grandaliano G., Di Paolo S., Monno R., Stallone G., Ranieri E., Pontrelli P., Gesualdo L., Schena F.P. Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: the role of coagulation and fibrinolysis in renal graft fibrosis. Transplantation 2001, 72:1437-1443.
253. de Gouville A.-C., Boullay V., Krysa G., Pilot J., Brusq J.-M., Loriolle F., Gauthier J.-M., Papworth S.A., Laroze A., Gellibert F., Huet S. Inhibition of TGF-[beta] signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br. J. Pharmacol. 2005, 145:166-177.
254. Liu R.M. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid. Redox Signal. 2008, 10:303-319.
255. Jarman E.R., Khambata V.S., Cope C., Jones P., Roger J., Ye L.Y., Duggan N., Head D., Pearce A., Press N.J., Bellenie B., Sohal B., Jarai G. An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model. Am. J. Respir. Cell Mol. Biol. 2014, 50:158-169.
256. Mayoral R., Valverde A.M., Llorente Izquierdo C., Gonzalez-Rodriguez A., Bosca L., Martin-Sanz P. Impairment of transforming growth factor beta signaling in caveolin-1-deficient hepatocytes: role in liver regeneration. J. Biol. Chem. 2010, 285:3633-3642.
257. Samarakoon R., Chitnis S.S., Higgins S.P., Higgins C.E., Krepinsky J.C., Higgins P.J. Redox-induced Src kinase and caveolin-1 signaling in TGF-beta1-initiated SMAD2/3 activation and PAI-1 expression. PloS One 2011, 6:e22896.
258. Jiang Z., Seo J.Y., Ha H., Lee E.A., Kim Y.S., Han D.C., Uh S.T., Park C.S., Lee H.B. Reactive oxygen species mediate TGF-beta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem. Biophys. Res. Commun. 2003, 309:961-966.
259. Nakayama N., Nakamura T., Okada H., Iwaki S., Sobel B.E., Fujii S. Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-beta. Coron. Artery Dis. 2011, 22:468-478.
260. Huang Y., Haraguchi M., Lawrence D.A., Border W.A., Yu L., Noble N.A. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J. Clin. Investig. 2003, 112:379-388.
261. Huang Y., Border W.A., Lawrence D.A., Noble N.A. Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. Am. J. Physiol. Ren. Physiol. 2009, 297:F1045-F1054.
262. Huang Y., Border W.A., Lawrence D.A., Noble N.A. Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int. 2006, 70:515-522.
263. Rhyu D.Y., Park J., Sharma B.R., Ha H. Role of reactive oxygen species in transforming growth factor-beta1-induced extracellular matrix accumulation in renal tubular epithelial cells. Transplant. Proc. 2012, 44:625-628.
264. Samarakoon R., Higgins S.P., Higgins C.E., Higgins P.J. TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J. Mol. Cell. Cardiol. 2008, 44:527-538.